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Abstract Vesicular monoamine transporters (VMAT) catalyze transport of serotonin, dopamine, pinephrine and norepinephrine into subcellular 
storage organelles in a variety of cells. Accumulation of the neurotransmitter depends on the proton electrochemical gradient across the organelle 
membrane and involves VMAT-mediated exchange oftwo lumenal protons with one cytoplasmic amine. It has been suggested in the past that His 
residues play a role in H+ movement or in its coupling to active transport in H+-syrnporters and antiporters. Indeed VMAT-mediated transport is 
inhibited by reagents pecific for His residues. We have identitled one His residue in VMATl from rat which is conserved in other vesicular 
neurotransrnitter ransporters. Mutagenesis ofthis His (H419) to either Arg or Cys completely inhibits [%IBerotonin and [%Ijdopaxnine accumulation. 
Mutagenesis also inhibits other H+-dependent partial reactions of VMAT such as the acceleration ofbinding of the high affinity ligand reserpine, 
but does not inhibit the l-%Ilreserpine biding which is not dependent on H’ translocation. It is concluded that His-419 plays a role in energy coupling 
in >VMATl . 
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1. introduction 
Classical neurotransmitters are stored in synaptic vesicles 
and storage organelles of secretory cells. Transport of the 
monoamines serotonin, dopamine, norepinephrine, epine- 
phrine, and histamine into storage organelles in a variety of 
cells is catalyzed by a family of vesicular monoamine trans- 
porters (VMATs). Accumulation of the neurotransmitter de- 
pends on the proton electrochemical gradient generated by the 
vesicular H’-ATPase and involves the VMAT-mediated ex- 
change of two lumenal protons with one cytoplasmic amine 
PI. 
VMATs are known for their substrate promiscuity and they 
share substrates and inhibitors with multidrug transporters 
from bacteria and higher animals [4]. In addition, VMATs 
show a distinct homology to a class of proteins present in 
bacteria and yeasts which are known for their ability to confer 
resistance to drugs and antibodies. It has been suggested that 
members of this family (the TEXANS) may play a role in 
detoxification at the cellular level also in higher organisms by 
removal of toxic compounds away from their target into acidic 
subcellular organelles. 
Reserpine is a potent competitive inhibitor of VMAT which 
binds at the site of amine recognition and dissociates very 
slowly if at all from the transporter, even after solubilization 
[5]. Thus it has been used to label the transporter and follow 
its separation through a variety of procedures [6]. Changes in 
[3H]reserpine binding rate occur upon imposition of a trans- 
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membrane H+ gradient [7,8]. They probably reflect changes in 
the availability of reserpine binding sites, and translocation of 
a single H’ generates the binding form of the transporter [5]. 
The energy invested in the transporter by H’ flux is released 
by ligand binding and is converted into vectorial movement of 
a substrate molecule across the membrane or directly into bind- 
ing energy. In the case of a substrate, a second conformational 
change results in the ligand binding site being exposed to the 
vesicle interior, where the substrate can dissociate. The second 
H+ in the cycle, may be required to facilitate the conformational 
change or to allow for release of the positively charged sub- 
strate from the protein [5]. 
A clue for the molecular basis of some of these processes was 
obtained using phenylglyoxal (PG) and diethyl pyrocarbonate 
(DEPC), two reagents relatively specific for Arg and His resi- 
dues, respectively. They both inhibited VMAT-mediated sero- 
tonin accumulation in chromaffin granule membrane vesicles 
in a dose-dependent manner (IC50 of 8 and 1 mM, respectively) 
[9,10]. The inhibition by DEPC was specific for His groups 
since transport could be restored by hydroxylamine [9]. Neither 
PG nor DEPC inhibited binding of reserpine, indicating that 
the inhibition of transport was not due to a direct interaction 
with either of the known binding sites. Interestingly, however, 
the acceleration of reserpine binding by a transmembrane H’ 
gradient was inhibited by both reagents [9]. The results sug- 
gested that either proton transport or a conformational change 
induced by proton transport is inhibited by both types of rea- 
gents. 
Cloning of VMAT [11,12] made it feasible to try to identify 
the residue(s) modified by DEPC. In this report we present an 
analysis of the role of histidines in VMAT carried out by site 
directed mutagenesis of rVMAT1. There are five His in 
rVMAT1; out of them, three are not conserved amongst the 
VMAT family: these are two His (H62 and H95) which reside 
in the large glycosylation loop, and one (H164) in the loop 
between transmembrane segment 2 and 3. On the other hand, 
the two His, H384 and H419, are conserved to varying degrees: 
H384 in rat VMATl is conserved as a Lys in the other VMAT’s 
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and H419 is conserved as His throughout all the VMAT 
proteins known. As much as replacement of H384 with an Arg 
(H384R) has no effect whatsoever on transport activity, re- 
placement of H419 with either Cys (H419C) or Arg (H419R) 
completely abolishes transport as measured in permeabilized 
CVI cells transiently transformed with plasmids coding for the 
mutant proteins. Reserpine binding to the mutant proteins in 
the absence of L&+ is at levels comparable to those detected 
in the wild type. However, A&+ does not accelerate reserpine 
binding to either H419R or H419C proteins. These results sug- 
gest that His-419 is associated with H’ translocation or in 
conformational changes occurring after substrate binding. 
ing tracers and/or inhibitors as indicated for the specific experiments. 
At given time periods the reaction buffer was aspirated and discarded 
and the cells were washed with ice-cold uptake buffer containing 2 mM 
MgSO, and no tracers. The cells were then collected with 1% SDS and 
radioactivity assessed by liquid scintillation. All data presented are 
mean values of triplicates. 
2.2. rH]Reserpine binding assay 
2. Materials and methods 
2.1. Growth of cells, transfections and transport assays 
The protocol for functional expression ofrat VMATl was essentially 
as described by Erickson et al. [12]. CVl cellsgrown in 24-well collagen- 
treated plates were infected with recombinant vaccinia virus encoding 
bacteriophage T7 DNA polymerase [13] and after 30 min they were 
transfected with 2 ,ug of plasmid DNA coding for wt or mutant 
rVMAT1, using 6.4 pg transfection reagent per well (DOTAP-Boehrin- 
per). After 18-20 h cells were rinsed with uptake buffer containing 110 
mM potassium tartrate, 5 mM glucose, 0.2% BSA, 200 PM MgC&, 
1 mM ascorbic acid, 10 PM pargyline and 20 mM PIPES at pH 7.4. 
Cells were permeabilixed for 10 min at 37°C in uptake buffer containing 
10 PM digitonin. The medium was removed and replaced with fresh 
buffer without digitonin containing 5 mM MgATP and the correspond- 
For measurement of [311jreserpine binding, cells were grown in 6 well 
plates, infected and transfected with proportionally higher amounts of 
material. rI-Ijreserpine binding was measured in lysates prepared from 
cells 1620 h after transfection. Cells were collected with a rubber 
policeman, centrifuged and resuspended in lysis buffer that contains 
0.15 M NaCl, 10 mM K-HEPES pH 8.5,5 mM MgCl,, 5 mM NaEGTA 
and 1 @ml leupeptin. After an additional centrifugation, cells were 
resuspended in the above buffer (250 @l/10’ cells) and sonicated in a 
bath sonicator for 90 s. Unbroken cells were discarded (3,500 x g, 
2 min) and the lysate was used to assay binding essentially as previously 
described 151. The lysate (containing 60-100 ~g protein) was diluted in 
a solution-c&air&g 320 mM sucrose, 10 mM K-HEPES, pH 8.5,4 
mM KCl, 5 mM ATP and 4 mM MgSO,. [3HJReserpine (20 cilmmol) 
was added to 3 nM or as indicated in the text, and the mixture was 
incubated at 32’C. After incubation for the time indicated, a 200 ~1 
sample of the suspension was applied to a 3-ml column of Sephadex 
LH-20 @repacked in a disposable syringe by centrifugation for 90 s in 
a clinical centrifuge), centrifuged for 2 min and the effluent was assayed 
for radioactivity. The assays were performed in duplicates and parallel 
reaction mixtures, containing 2 pM reserpine were used to subtract 
nonspecific binding which was typically less than 10% of the binding 
to membranes from VMAT-expressing cells. All data presented are 
mean values of duplicates. 
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Fig. 1. Histidine-384 is not essential for rVMATl-mediated serotonin transport and reset-pine binding. CVI cells were infected with vaccinia virus 
and transformed with the pTM1 plasmid bearing either wild type rVMAT1 (m) or H384R (0) mutant as described in section 2. (A) Transport was 
assayed in digitonin permeabiliied cells after incubation with [)H]serotonin (0.2 PM, 25.7 Wmmol). (B) [3H]Reserpine binding was tested in total 
lysates (70 jfg protein) prepared from each type of cell and assayed after incubation with 3 nM of the drug (20 Cilmmol). 
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2.3. Plasmids 
For transient functional expression rVMAT1 was subcloned in the 
hiah exoression vector DTM~ essentiallv as described for bVMAT2 1141. 
T\;o pmners were synihesized in order to excise the coding sequence 
of the rat VMATl sequence from a Blueseript plasmid carrying the 
whole sequence ofrVMAT1. The sense primer starts at nucleotide 262, 
which is 2 bp upstream of the ATG initiation codon, and introduces 
an EcoRI site at the 5’ end of the primer. The reverse primer was the 
Ml3 commercially available primer (Cat. # 1201 from New England 
Biolabs Inc.) which is homologous to sequences in the Bluescript plas- 
mid. After PCR amplification, the 2,200 bp fragment was separated on 
an agarose gel and extracted by the QIAEX gel extraction kit 
(QIAGEN). The fragment was then cut by XhoI and EcoRI restriction 
endonucleases and ligated into pTM1 vector digested with the same 
enzymes. As a result of such ligation, translation of VMATl starts from 
the ATG initiation codon of the pTM1 vector, and the protein syuthe- 
sized contains a total of four additional amino acids at its amino 
terminus (MGIP). Such an addition did not impair the activity in any 
noticeable way and expression levels were 3-4 times higher than those 
in Bluescript. 
2.4. Mutagenesis 
Mutants were obtained by PCR mutagenesis u ing the overlap exten- 
sion procedure described by Ho et al. [18]. For each mutation a set of 
two overlapping oligonucleotide primers containing the desired muta- 
tion were constructed. The outside primers were homologous to bp 
531-557 and 16&1628 of VMATl in the case of the H419 mutations; 
in the case of the H3t34 mutation the reverse primer was the external 
Ml3 mimer. # 1201. The resultina mutaeenised PCR uroduct (1133 
and 2bOO bR for the H419 and the-H384 mutations res&tively)were 
digested with BclI and Pm1 for H419 and Sac1 and SSe83871 for 
H384. The H419 mutations were first cloned into Bluescript predigested 
with the proper enzymes and only later transferred topTM1. The H384 
mutation was cloned directly into pTM1. In each case the mutagenised 
fragment was sequenced toverify the mutation and to ensure no other 
mutations occurred uring the amplification process. Sequencing was 
conducted with the Sequenase. kit (version 2.0, United States Biochem- 
ical). 
3. Results 
Two histidine residues are conserved amongst various 
VMATs: His-384 of rVMAT1 is conserved as a positive charge 
(Lys) in all the other VMATs; His-419 is fully conserved in all 
five VMAT sequences available [4]. In order to gain insight into 
the role of these two conserved His in energy coupling and 
substrate binding, they were mutagen&d into either Arg or 
Cys residues, and activity of the mutated protein was assayed. 
3.1. His-384 is not essential for activity 
His-384 was replaced with Arg and the activity of the resnl- 
tant protein was assayed in CVl cells. Transport of [3H]sero- 
tonin into CVl cells was measured following infection with 
recombinant vaccinia virus (encoding T7 polymerase) and 
transfection with the cDNA coding for wild type or H384R 
rVMAT1 under the control of T7 promoter. Cells were perme- 
abilized with digitonin as described by Erickson and col- 
laborators [12]. When cells were transfected wi& wild type 
rVMAT1 or H384R, [3H]serotonin was accumulated in a time- 
dependent fashion and uptake was maximal at 5-15 min (Fig. 
1A). Accumulation decreased after longer incubation periods 
(> 30 min) due to detachment of the digitonin-permeabihzed 
cells as observed visually. Both the rate and extent of uptake 
were indistinguishable in cells transformed with a plasmid cod- 
ing for the wild type protein or for the H384R mutant. In both 
cases transport was completely inhibited in the presence of 10 
FM of the proton ionophore CCCP as expected from the well 
known properties of VMAT, and by 1 ,uM reset-pine which is 
a potent competitive inhibitor of monoamine transport (data 
not shown). Binding of rH]reserpine to the mutant protein was 
indistinguishable from that of the wild type (Fig. 1B). In this 
experiment, membranes from CVl-cells transformed with the 
wild type VMAT and the H384R mutant were allowed to bind 
[3H]reserpine for various times, in the presence of ATP. A 
time-dependent increase was observed with both membranes 
that reached equilibrium after about ten minutes at levels of 
about 1.0 pmol/mg protein. The findings described in these 
experiments demonstrate that His-384 is not essential for trans- 
port. 
3.2. Replacement of His-419 with either Cys or Arg completely 
abolishes transport catalyzed by r VMATI 
Strikingly, however, when His-419 was replaced with either 
Arg or Cys the effect on [3H]serotonin transport activity was 
very dramatic. Fig. 2 shows the transport activity of cells trans- 
formed with H419, H419R, H419C or a mock transformation 
with vector that contains no insert @TMl). Cells transformed 
with wild type (H419) rVMAT1 showed a time-dependent 
reserpine-sensitive accumulation of [3H]serotonin. Cells trans- 
formed with either H419R or with H419C showed no measur- 
able activity above the background levels as measured in mock- 
transformed cells. Although the data are not shown, essentially 
the same results were obtained when [3H]dopamine, another 
substrate of rVMAT1 was used (15 nM, 32.2 Wmmol) or when 
the concentration of [3H]serotonin was increased tenfold to test 
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Fig. 2. Replacement of His419 with either Arg or Cys inactivates 
transport by rVMAT1. CVl cells were infected with vaccinia virus and 
transformed with pTM1 plaamid bearing either wild type rVMAT1 (H), 
or H419R (0) and H419C (A) mutants or mock transformed with the 
plasmid with no insert (+) as described in section 2. Transport was 
assayed in digitonin permeabilized cells after incubation with [%&ero- 
tonin (0.2 pM, 25.7 Ci/mmol). 
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Fig. 3. Effect of ~@a+ on [3H]reserpine binding by the mutant protein H419R. [‘H]Reserpine binding (3 nM, 20 Ci/mmol) was measured in lysates 
prepared from CVl cells transformed with wild type plasmid (w and q ), H419R (o and 0), H419C (A) or pTM1 with no insert (+ and 0). (A) All 
the reactions were carried out in the presence of ATT? (B) Wild type and H419R in the presence (closed symbols) and in the absence. (open symbols) 
of ATP. C) All the reactions were carried out in the absence of ATP 
for a possible I&, effect. To assess whether the mutants are able 
to catalyze partial reactions of the catalytic cycle, [3H]reserpine 
binding to membranes prepared from transformed cells was 
measured in the presence of ATP. Under these conditions 
(3 nM reserpine), the wild type protein bound [‘IQeserpine in 
a time-dependent manner and reached an apparent equilibrium 
after about 20 min reaction (Fig. 3A). [31-I’JReserpine binding 
to the H419R and the H419C proteins was lower than binding 
to the wild type protein (0.38 pmol as compared to 1.4 in the 
wild type). Binding to the mutant proteins, although lower, was 
significant and easily detectable and could be inhibited by addi- 
tion of unlabelled reserpine (2 PM, not shown) to the levels 
observed in membranes from mock-transformed cells. As pre- 
viously reported, [3H]reserpine binding is accelerated in the 
presence of ATP or an artificial A&+ [7,8]. Therefore, addition 
of uncouplers such as CCCP reduced the binding levels signifi- 
cantly. Surprisingly, however, although the binding to the wild 
type protein and to mutant H384R was inhibited by CCCP, no 
effect on the binding to the mutant protein H419R was detected 
(Table 1). This finding was further investigated by analyzing the 
effect of ATP on the binding to the mutant proteins. As ex- 
pected, binding to the wild type transporter was accelerated 
several fold in the presence of A,i&+ (Fig. 3B). Binding in the 
absence of L$.&+ was slower but reached equilibrium at levels 
comparable to those observed in the presence of ATP after 
longer incubation period (Fig. 3C). When the wild type and 
H419R were compared in the absence of ATP, there was prac- 
tically no difference in the rate of binding (Fig. 3B) and only 
a 40% decrease in the equilibrium level after 4 h was detected 
(Fig. 3C). In agreement with the fact that CCCP, which col- 
lapsed the Aj&+, did not decrease the binding level of the mu- 
tant, also ATP, that is hydrolyzed by the V-ATPase to generate 
a A&+, had no effect on the rate of binding of the mutant 
protein (Fig. 3B). 
It was previously reported that only the binding rate but not 
the apparent affinity of the transporter to reserpine or the 
number of binding sites were modified by L&+ ([8] and Fig. 41. 
Binding was biphasic with two apparent affinities, both in the 
absence and presence of L&+. The results summarized in the 
Scatchard plots shown in Fig. 4A and B demonstrate that the 
Table 1 
Effect of CCCP on [3H]reserpine binding to wild type and mutant 
proteins 
Control + CCCP 
(pmol/mg protein) (pmol/mg protein) 
Wild type 1.35 f 0.07 0.54 + 0.06 
H384R 1.66 + 0.09 0.68 k 0.06 
H419R 0.53 + 0.07 0.46 f 0.07 
[sH]Reserpine binding was measured in lysates prepared from CVl cells 
transformed with wild type plasmid or the indicated mutants. Reaction 
was carried out for 30 min and CCCP concentration was 5 PM. 
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Fig. 4. The number of reserpine binding sites in membranes from wild type and H419R-transformed cells is identical. [%IjReserpine binding was 
measured at various concentrations of the drug in lysates prepared from CVl cells transformed with wild type plasmid (o and H) and mutant H419R 
(0). The assay was performed in the presence (a) or absence of ATP (O and 0) for 40 and 120 min, respectively. 
high affinity binding site (& = 0.58 nM) is sparse (0.6 and 1.2 may be helpful in understanding the details of the various 
pmol/mg protein, respectively in the presence and absence of processes ince the different steps can be isolated and studied 
ATP) compared to the more abundant (10.9 pmol/mg protein) low separately. Moreover, as mentioned above, the H419R mutant 
affinity site (25-30 nM). Interestingly, in the mutant protein protein does not display high affinity binding of [3H]reserpine 
only the low a!Bnity site (15 nM) was detected, with a practically which may suggest hat the His-419 residue plays also a role in 
identical site density (10.2 pmol/mg protein) (Fig. 4C). substrate binding. 
4. Discussion 
In summary, replacement of His419 with either At-g or Cys 
residues caused a loss in the transport activity of VMATI and 
in its ability to respond to A&+. The rate of r3H]reserpine 
binding in H419R or H419C was not modiied by A/&+. The 
total amount of [3H]reserpine bound to the H419R protein and 
its affinity were very similar to those observed in the wild type 
protein except that the high affinity site, which corresponds to 
the binding of about 10% of the ligand, was not detectable in 
the mutant. The findings also demonstrate that the expression 
levels of the various mutants are very similar to those of the 
wild type as judged by the density of the reserpine binding sites. 
These findings were corroborated by Western blot analysis of 
the protein levels of the various mutants using an antibody 
directed against sequences in the C terminus of rVMAT1 
(kindly supplied by R.H. Edwards, UCLA). 
Based on the studies presented in this paper, it is tempting 
to speculate that histidine 419, an amino acid with a pK in the 
physiological range may play a direct role in the transport of 
the proton involved in the translocation cycle. It is also possi- 
ble, however, that it plays a more indirect role, in the conforma- 
tional change required for the cycle to function. A role for 
histidine residues in sensing proton concentration and in cou- 
pling of H’ movements to solute movement has been proposed 
in several cases in E. coli, most notoriously in NhaA, a Na’lH’ 
antiporter and the luc permease, aB-galactoside-H’ symporter 
[15-17. Both, in the luc permease and in rVMAT1, treatment 
with DEPC or mutagenesis of the proper His residue yield a 
very similar phenotype: transport and all the partial reactions 
dependent on Aj&+ are inhibited, while ligand binding and 
reactions which do not require H+ translocation are not im- 
paired. 
The nature of the two types of binding sites, their intercon- 
version and the effect of A&+ on each of the forms is not fully 
understood yet. The mutants described in this communication 
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